

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 17, 2020**

---

**PIERIS PHARMACEUTICALS, INC.**  
(Exact Name of Registrant as Specified in its Charter)

---

**Nevada**  
(State or other jurisdiction of  
Incorporation)

**001-37471**  
(Commission  
File Number)

**EIN 30-0784346**  
(IRS Employer  
Identification No.)

**255 State Street, 9<sup>th</sup> Floor**  
**Boston, MA** **02109**  
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code: 857-246-8998**  
**N/A**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	PIRS	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events**

The 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) of Pieris Pharmaceuticals, Inc. (the “Company”) will be held on June 23, 2020. The deadline for the receipt of any stockholder proposals for inclusion in the proxy statement for the 2020 Annual Meeting will be on or before the close of business on February 22, 2020 and the deadline for the receipt of any stockholder proposals for inclusion at the 2020 Annual Meeting is no earlier than February 24, 2020 and no later than March 25, 2020. Because the date of the 2020 Annual Meeting represents a change of more than thirty (30) days from the anniversary date of the 2019 Annual Meeting of Stockholders, which was held on July 31, 2019, the Company is providing this information in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PIERIS PHARMACEUTICALS, INC.

Dated: January 17, 2020

/s/ Tom Bures

---

Tom Bures

Vice President, Finance